Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor

Translational Oncology

Volumn 4, Issue 2, 2011, Pages 110-121

  Hillman, Gilda Gali ^a   Singh Gupta, Vinita ^a   Al Bashir, Areen K ^a   Yunker, Christopher K ^a   Joiner, Michael C ^a   Sarkar, Fazlul H ^a   Abrams, Judith ^a   Mark Haacke, E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G 4660; GADOLINIUM PENTETATE; ISOFLAVONE DERIVATIVE; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CELL STRUCTURE; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY TUMOR; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; RADIATION DOSE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 79953661486     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10274     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. Motzer RJ, Bander NH, and Nanus DM (1996). Renal-cell carcinoma. N Engl J Med 335, 865-875.
3. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, and Crawford ED (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345, 1655-1659.
4. Jain RK (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989.
5. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
6. Basappa NS, Elson P, Golshayan AR, Wood L, Garcia JA, Dreicer R, and Rini BI (2010). The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer; Epub ahead of print.
7. Rixe O and Rini B (2010). Renal cell carcinoma: ten years of significant advances. Target Oncol 5, 73-74.
8. Rini BI (2010). New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16, 1348-1354.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27, 3584-3590.
11. Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, and Haacke EM (2009). Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia 11, 910-920.
12. Hillman GG, Singh-Gupta V, Al-Bashir AK, Zhang H, Yunker CK, Patel AD, Sethi S, Abrams J, and Haacke EM (2010). Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol 3, 293-306.
13. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9, 327-337.
14. Abrams TJ, Lee LB, Murray LJ, Pryer NK, and Cherrington JM (2003). SU11248 inhibits KITand platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2, 471-478.
15. Kelly RJ and Rixe O (2009). Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 4, 297-305.
16. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al. (2008). Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14, 7272-7283.
17. Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, Kucuk O, and Sarkar FH (2007). Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer 7, 4.
18. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, and Teh BT (2010). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70, 1053-1062.
19. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. (2006).Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24, 16-24.
20. Telli ML, Witteles RM, Fisher GA, and Srinivas S (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 9, 1613-1618.
21. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, and Schmidinger H (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26, 5204-5212.
22. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, and Sarkar FH (2004). Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3, 1271-1279.
23. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, and Hillman GG (2006). Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6, 107.
24. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, and Hillman GG (2007). Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 67, 2141-2149.
25. Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, Kucuk O, Sarkar FH, and Hillman GG (2007). Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 120, 2491-2498.
26. Singh-Gupta V, Zhang H, Banerjee S, Kong D, Raffoul JJ, Sarkar FH, and Hillman GG (2009). Radiation-induced HIF-1α cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer 124, 1675-1684.
27. Singh-Gupta V, Zhang H, Yunker CK, Ahmad Z, Zwier D, Sarkar FH, and Hillman GG (2010). Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharm Res 27, 1115-1127.
28. Messina M, Kucuk O, and Lampe JW (2006). An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 89, 1121-1134.
29. Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, Cher ML, Andic F, Rossi PJ, and Kucuk O (2010). Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer 62, 996-1000.
30. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 3731-3736.
31. Hylton N (2006). Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24, 3293-3298.
32. Rimbach G, Boesch-Saadatmandi C, Frank J, Fuchs D, Wenzel U, Daniel H, Hall WL, and Weinberg PD (2008). Dietary isoflavones in the prevention of cardiovascular disease-a molecular perspective. Food Chem Toxicol 46, 1308-1319.
33. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, and Song CW (2002). Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62, 1702-1706.
34. Wachsberger P, Burd R, and Dicker AP (2003). Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9, 1957-1971.
35. Dicker AP, Williams TL, and Grant DS (2001). Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24, 438-442.
36. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, and Suit HD (2001).Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiationinduced long-term control of human tumor xenografts. Cancer Res 61, 39-44.